Strategic partnerships will allow us to reach our goal



Vantum Corporate: Chief Financial Officer (CFO). Independent financial and strategic consultancy firm specialized in start-ups and innovative SMEs with high growth potential.


Genesis Biomed: GENESIS Biomed is a start-up formed by entrepreneurs and with vocation of service to entrepreneurs and research centres, offering consulting services in strategy, business development, regulatory affairs and fundraising.


IR-Hospital de Sant Pau: The Research Institute of the Hospital de la Santa Creu i Sant Pau (HSCSP-IR) was created on 4 June 1992 as a private scientific foundation. Its mission is to promote basic, clinical, epidemiological and healthcare research in the health science and biomedical fields, with the aim of improving the health of the population. On 10 December 2003, the Autonomous Government of Catalonia approved affiliation of the HSCSP-IR as a University Research Institute attached to the Autonomous University of Barcelona (UAB).


IIB Sant Pau: The IIB Sant Pau was founded on 17 May 2009 as the culmination of efforts by the HSCSP-IR and nine other related bodies to cooperate as part of a high-level research centre that would develop new techniques and processes aimed at improving the quality of life of the population.



Caixa Capital Risc: Venture capital arm of “la Caixa”, that invests in innovative SMEs in the early phases. Caixa Capital Risc currently manages nearly €200 million through eight investment vehicles and has a portfolio of 195 companies. It is a multisector investor that focuses mainly on emerging sectors: technology, digital industry, industrial technology and the life sciences. In addition to its investment activity, Caixa Capital Risc also carries out programmes to promote the transfer of research and to guide innovative enterprises and projects with high potential for growth.


Healthequity SCR: Venture capital fund that invests in companies in the early stages of development in the healthcare sector, focusing mainly on biotechnology and medical devices. Founded by the Barcelona Medical Association and the Riva y García financial group, HealthEquity looks for projects at companies in the health sciences sector to develop on the market, as well as helping foster the Catalan and Spanish biotechnology ecosystem.



EU: This project has received funding from the European Union’s Horizon 2020 (SME Instrument) research and innovation programme under grant agreements:

  • Phase 1: No. 826930
  • Phase 2: No. 849047



EIT Health: This project has received funding from the EIT Health’s Headstart Funding Programme 2018, has been selected as semi-finalist at the EIT Health’s Catapult Competition 2018 and granted with a Digital Sandbox Programme 2020.



ENISA: GlyCardial Diagnostics has also received the support from ENISA (Ministerio de Industria, Comercio y Turismo).



RETOS COLABORACION: Financiado por FEDER / Ministerio de Ciencia, Innovación y Universidades – Agencia Estatal de Investigación / Proyecto Apo J-Glyc en la isquemia cardiovascular (AGLIC) Expediente RTC-2017-6710-1



PROGRAMA NEOTEC: Subvencionado por el Centro para el Desarrollo Tecnológico Industrial (CDTI) (Referencia Proyecto: SNEO-20181107)



Oficina Española de Patentes y Marcas: Ayudas de la OEPM para el fomento de solicitudes de patentes y modelos de utilidad 2019.